(Total Views: 683)
Posted On: 01/24/2021 12:51:41 AM
Post# of 156921
BLA filing Q2 2021.
For Gilead I'm guessing you're talking about lenacapavir. According to the trial protocol lenacapavir must be taken with another HIV treatment regimen because of potential to develop resistance. So in usage it would be the equivalent of leronlimab in it's combo trial. However with monotherapy it would be leronlimab once weekly (possibly longer in the future) for lenacapavir it would be a daily regimen of HAART drugs and lenacapavir every 6 months.
From what little has been released in their trial they had statistical significance in viral load reduction at 14 days but have not released whether that has stayed stable over a longer period of time.
For Gilead I'm guessing you're talking about lenacapavir. According to the trial protocol lenacapavir must be taken with another HIV treatment regimen because of potential to develop resistance. So in usage it would be the equivalent of leronlimab in it's combo trial. However with monotherapy it would be leronlimab once weekly (possibly longer in the future) for lenacapavir it would be a daily regimen of HAART drugs and lenacapavir every 6 months.
From what little has been released in their trial they had statistical significance in viral load reduction at 14 days but have not released whether that has stayed stable over a longer period of time.
(1)
(0)
